STALE?Report written 6 days ago · at $32.50entry levels may be stale — re-check before acting
VERA
ค่าขนมMID CAP
Vera Therapeutics, Inc. · NASDAQ · Healthcare / Biotechnology (Nephrology)
$32.50
▼ 0.12%
MCap $2.34B
Roughly flat today, but up from $29.95 on the last report (Aug 5) after the Sep 15 ORIGIN 3 confirmatory Phase 3 data hit its primary endpoint (p<0.0001) — JPMorgan raised its target to $83 from $76 on the print. Still well off the 52-week high ($56.05); the stock hasn't fully re-rated toward the print despite two consecutive positive regulatory/clinical outcomes.
BusinessKidney-disease biotech · TRUTAKNA (atacicept) has FDA accelerated approval (Jul 7, 2026) for high-risk IgA nephropathy AND now a POSITIVE ORIGIN Phase 3 confirmatory readout (Sep 15, 2026, p<0.0001) — sBLA for full approval targeted Q4 2026
Thesis
The original catalyst FIRED and came in clean: the ORIGIN 3 Phase 3 confirmatory readout (Sep 15, 2026) hit its primary eGFR endpoint (-0.6 mL/min/1.73m²/yr with TRUTAKNA vs -5.6 with placebo, p<0.0001) with a 76% reduction in composite kidney-disease-progression events (HR 0.24) — the last major clinical binary before full approval, on top of the accelerated approval already won Jul 7. Thesis is STRENGTHENED, not just intact: JPMorgan raised its target to $83 from $76 on the data. Yet the stock is only up ~8.5% since the last report ($29.95→$32.50) — the market wants to see the Q4 2026 sBLA actually filed before pricing in full approval. Well-capitalized ($499.2M cash as of Q2 2026, net loss $109.5M/qtr) with no survival concern. Position size 2-5% max; per the turbo lane's entry-rule prior (entryGuidance.turbo, n=19), chasing a name into a resolved catalyst has historically returned a median -13.7% by the next measurement point — Entry 1 is NOT preferred here, the dip (Entry 2) is.
📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม
ค่าขนม — thesis STRENGTHENED: the Sep 15 ORIGIN 3 confirmatory data hit p<0.0001, clearing the last major clinical binary before full approval. But the entry-rule prior (n=19) shows a -13.7% median return chasing a name into a resolved catalyst — don't buy the pop, wait for the dip (Entry 2).
81
score / 100 ⓘ
⚡ Catalyst
🧬 ORIGIN 3 Phase 3 Confirmatory Data — POSITIVE (resolved)RESOLVED
The FDA-agreed, moved-up primary eGFR analysis read out Sep 15, 2026: eGFR slope -0.6 vs -5.6 placebo (p<0.0001), composite kidney-disease-progression events cut 76% (HR 0.24). This clears the clinical binary underpinning the case for full approval and drove JPMorgan's target raise to $83.
Sep 15, 2026
📄 sBLA Filing for Full ApprovalQ4 2026
Vera targets filing a supplemental Biologics License Application in Q4 2026, now backed by the positive ORIGIN 3 confirmatory data, to convert TRUTAKNA's accelerated approval into full approval — company guides full approval could land in 2027.
Ongoing commercial rollout since the Jul 7 approval; the next visibility point on launch economics (prescriptions, payer coverage, revenue ramp vs launch spend) is the Q3 2026 earnings call, expected ~Nov 2026 — exact date not yet scheduled.
~Nov 2026
🎯 Entry Point
Entry 1
$32.50
Current price — post two consecutive positive catalysts. NOT preferred: the turbo entry-rule prior (entryGuidance.turbo, n=19) shows a median -13.7% return chasing a name into/after a resolved catalyst (78.9% of cases negative)Now (not preferred)
Entry 2PREFERRED
$27.5–29.5
Dip zone, roughly -9% to -15% off current — matches the -13.7% median pullback the entry-rule prior measures from report price forwardIf dips
Entry 3
$23.50
Deep dip — near the 52-week low ($23.05), only on a broad biotech selloff or a material sBLA-filing delayDeep dip only
✅ Take Profit
TP1
Base — assumes a ~9-12 month horizon: sBLA filed on schedule in Q4 2026 plus commercial-launch metrics stabilize over the next two quarters. Written well above the turbo lane's realized 30-day P75 (12.2%) and P90 (25.9%) because this is a multi-quarter execution re-rate, not a single 30-day catalyst pop — flagging that against the lane's +72.7pp historical optimism bias.
$47.13
+45%
TP2
Bull — hits the 14-analyst consensus average; full-approval process (sBLA → decision) completes broadly on guided timeline, ~12-18 month horizon
$77.5
+138.5%
TP3 🌙
Moon — hits the single highest named target; blockbuster commercial ramp + full approval + possible label expansion, ~18-24 month horizon
$100
+207.7%
🔴 Stop Loss
Tight Stop
Below 52-week-low support — wider than the fda_decision-type median MAE (-18.4%, n=10 per the turbo feedback prior), since a name that already cleared two binaries deserves room, not a tight technical stop
$23.5
-27.7%
Hard Stop
Well below the 52-week low — would imply a genuinely failed commercial launch or a surprise setback on the full-approval pathway despite the clean confirmatory data
$18
-44.6%
Risk / Reward
From Entry 2 ($28.50 mid), tight stop vs TP2
5.0 : 1
⚠ Solid R/R for a name that already cleared its two biggest binaries — Moon case still leans on one analyst's outlier target, treat cautiously
📅 Estimate Date
ORIGIN 3 Phase 3 eGFR Analysis
RESOLVED — hit primary endpoint p<0.0001, 76% reduction in composite progression events
Sep 15, 2026 ✓
Positive readout
sBLA Filing (Full Approval)
Now backed by positive confirmatory data
Q4 2026
Sets up eventual full-approval decision in 2027
📈 Possible Up % — Scenario Spread
Bear
-33%
$21.78
Base
+45%
$47.13
Bull
+138.5%
$77.5
Moon
+207.7%
$100
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM
Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution
Rate Outlook
Fed unexpectedly hiked 25bp to 3.75-4.00% on Sep 16, 2026 (unanimous 12-0), reversing the market's prior read that hike odds were fading after a weak July jobs print (-23K vs +80K expected, Aug 7) — a genuinely hawkish surprise for the rate path into year-end
Inflation
FOMC's own statement cites elevated inflation and targets 'a timelier return to the 2% goal' — inflation concern, not labor softness, dominated this decision
Sector Impact
VERA's near-term drivers (sBLA filing, commercial launch execution) are clinical/regulatory/execution-driven, not financing-dependent, and the company is well-capitalized ($499.2M cash) and already commercial — this stays one of the more macro-independent names on the board despite the hawkish surprise
Summary
MEDIUM — the surprise hike raises the cost-of-capital backdrop for biotech broadly, but VERA's own catalysts don't route through financing, so the direct read-through to this specific thesis is limited
🎯 Analyst Targets
Wall Street price targets vs the current price — cross-check our TP levels
Consensus (14 analysts)
Strong Buy$77.5+138%
JPMorgan
Buy$83+155%
Highest named target
Buy$100+208%
current price $32.50
🔍 Similar-Catalyst Comparable Check
Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic
VERA✅ GoodJul 7, 2026
+7.05%
in 1 day
FDA accelerated approval for TRUTAKNA in high-risk IgA nephropathy
Same-company precedent for the first regulatory binary, already realized — a real but muted single-day reaction; the market has continued to demand commercial and confirmatory-data proof before re-rating further, a pattern that repeated after the Sep 15 Phase 3 data.
CELC❌ BadJul 15, 2026
-16%
in 1 day
REVTORPYK (gedatolisib) FDA approval, followed by delayed launch-timeline guidance
A directly comparable pattern — a clean FDA approval still produced a sharp drop once management guided a slower commercial launch than expected, the exact launch-execution risk VERA carries into its Q3 2026 earnings check.
KPTI❌ BadAug 2026
-69%
in 1 day
Phase 3 XPORT-EC-042 endometrial cancer trial primary-endpoint miss
The sector base rate for a genuine confirmatory Phase 3 miss — shows how much worse VERA's Sep 15 ORIGIN 3 readout could have gone; instead it cleared cleanly (p<0.0001), which is the core reason this thesis is now de-risked rather than broken.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode
Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.
⚠️
Use this stop-loss set (-28% / -35%) only when trading the earnings spot — not for the core holding (use the -27.7% / -44.6% set above). If you are holding long-term, follow the core set.
📈Pre-Catalyst Run-up Pattern
modest single-digit-to-low-teens % gains into each date, based on VERA's own pattern1-3 weeks before each confirmed event date
VERA ran up ahead of both the Jul 7 accelerated-approval decision and the Sep 15 ORIGIN 3 confirmatory readout as anticipation built — real same-name precedent for pre-event positioning
🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +15%
range: +7% to +30%· Jul 2026 & Sep 2026 (VERA)
VERA's own Jul 7 accelerated approval drove a +7.05% single-day gain. The Sep 15 ORIGIN 3 confirmatory data (p<0.0001, 76% reduction in composite progression) then drove JPMorgan to raise its target to $83 from $76 — but the stock has only re-rated modestly since (~$30 to $32.50), suggesting the market wants the sBLA actually filed, not just positive data, before pricing in full approval. fda_decision is a Tier-2 LEADER bucket in the turbo feedback prior (n=10, +9.3pp median excess vs SPY, gap +7.3 vs the overall +2pp) — a real tailwind cited here.
❌ Catalyst Missavg -35%
range: -16% to -69%· Jul 2026 (CELC) / Aug 2026 (KPTI)
Two relevant downside patterns from the same window: Celcuity (CELC) fell -16% on Jul 15, 2026 despite a clean FDA approval, purely on a delayed commercial-launch timeline guide — the launch-execution risk VERA itself now faces post-approval; a genuine confirmatory Phase 3 miss can be far worse, as Karyopharm (KPTI) fell -69% on an Aug 2026 Phase 3 primary-endpoint miss (VERA's own confirmatory readout already cleared this risk on Sep 15).
💼Spot Position Sizing
How the recommended % is derived
3%
of portfolio
Two of the name's three major binaries (accelerated approval, Phase 3 confirmatory data) are already resolved positively and the company is commercial + well-capitalized ($499.2M cash) — lower survival/binary risk than a typical turbo name, but correspondingly lower remaining asymmetry (Moon case now ~208% vs a fresh binary's 300%+), so sizing stays modest rather than scaling up just because risk fell
🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-28%($23.5)
Below the 52-week-low support zone ahead of the Q4 2026 sBLA filing — thesis-neutral pullback territory
After Catalyst (Bad Result)-35%
If the sBLA filing slips materially past Q4 2026, or early signals point to CRL risk on the eventual full-approval decision, exit